Journal article
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.
- Solomayer EF Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Saarland, Homburg. Electronic address: erich.solomayer@uks.eu.
- Gebauer G Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg.
- Hirnle P Department of Radiation Oncology, Central Academic Hospital, Bielefeld.
- Janni W Department of Gynecology and Obstetrics, Heinrich-Heine University, Düsseldorf.
- Lück HJ Department of Gynecologic Oncology, Hannover Medical School, Hannover, Germany.
- Becker S Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Saarland, Homburg.
- Huober J Breast Center, Department of Senologie, Kantonsspital St. Gallen, St. Gallen, Switzerland.
- Krämer B Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Saarland, Homburg.
- Wackwitz B Norvartis Oncology, Department of Medical Affairs, Nuremberg.
- Wallwiener D Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany.
- Fehm T Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Saarland, Homburg.
- 2012-03-03
Published in:
- Annals of oncology : official journal of the European Society for Medical Oncology. - 2012
Adult
Aged
Antineoplastic Agents
Arthralgia
Bone Marrow Cells
Bone Neoplasms
Breast Neoplasms
Diphosphonates
Female
Humans
Imidazoles
Middle Aged
Neoplasm Recurrence, Local
Neoplastic Cells, Circulating
Treatment Outcome
Zoledronic Acid
English
BACKGROUND
The presence of disseminated tumor cells (DTCs) in bone marrow of patients with early breast cancer (EBC) has been correlated with increased risk of metastatic disease or locoregional relapse. Zoledronic acid (ZOL) treatment has reduced DTCs in the bone marrow of patients with EBC in several studies. This controlled study sought to confirm these observations.
PATIENTS AND METHODS
Patients with EBC and DTC-positive bone marrow were randomized (N = 96) to treatment with ZOL plus adjuvant systemic therapy or adjuvant systemic therapy alone. The change in DTC numbers at 12 months versus baseline was measured.
RESULTS
DTC-positive patients treated with ZOL were more likely to become DTC-negative after 12 months of treatment compared with the controls (67% versus 35%; P = 0.009). At 12 months, DTC counts decreased to a mean of 0.5 ± 0.8 DTCs in the ZOL group and to 0.9 ± 0.8 DTCs in the control group. In addition, ZOL was generally well tolerated.
CONCLUSIONS
Treatment with ZOL improves elimination of DTCs. Further studies are needed to determine whether the reduction in DTCs by ZOL provides clinical benefit.
The presence of disseminated tumor cells (DTCs) in bone marrow of patients with early breast cancer (EBC) has been correlated with increased risk of metastatic disease or locoregional relapse. Zoledronic acid (ZOL) treatment has reduced DTCs in the bone marrow of patients with EBC in several studies. This controlled study sought to confirm these observations.
PATIENTS AND METHODS
Patients with EBC and DTC-positive bone marrow were randomized (N = 96) to treatment with ZOL plus adjuvant systemic therapy or adjuvant systemic therapy alone. The change in DTC numbers at 12 months versus baseline was measured.
RESULTS
DTC-positive patients treated with ZOL were more likely to become DTC-negative after 12 months of treatment compared with the controls (67% versus 35%; P = 0.009). At 12 months, DTC counts decreased to a mean of 0.5 ± 0.8 DTCs in the ZOL group and to 0.9 ± 0.8 DTCs in the control group. In addition, ZOL was generally well tolerated.
CONCLUSIONS
Treatment with ZOL improves elimination of DTCs. Further studies are needed to determine whether the reduction in DTCs by ZOL provides clinical benefit.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1093/annonc/mdr612
- PMID 22383680
- Persistent URL
- https://sonar.ch/global/documents/278345
Statistics
Document views: 21
File downloads: